The global Point of Care Diagnostics market size 2026 was valued at USD 32.87 billion in 2025 and is projected to grow from USD 34.47 billion in 2026 to USD 60.36 billion by 2034, at a CAGR of 7.26% during the forecast period. Point of care testing (POCT) refers to diagnostic testing conducted near the patient care site, enabling quick and accurate disease detection with minimal turnaround time.
Key Market Drivers
- Multiplex POC Platforms: The rising adoption of multiplex testing — which enables simultaneous detection of multiple pathogens or biomarkers from a single sample — is a primary growth driver. These platforms reduce testing time, lower operational costs, and align with the global push to decentralize diagnostic capabilities.
- Chronic Disease Prevalence: Growing incidence of diabetes, cardiovascular conditions, and infectious diseases continues to fuel demand. According to the CDC, diabetes prevalence in the U.S. grew by approximately 3.6% between 2021 and 2023.
- Technological Innovation: Advancements including CRISPR-based diagnostics, AI-powered tools, and IoT-integrated platforms are reshaping the market. In June 2025, NYU Abu Dhabi researchers announced a paper-based device capable of detecting infectious diseases including COVID-19 in under 10 minutes.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/point-of-care-diagnostics-market-101072
Market Restraints & Challenges
- Result Inconsistency: Variability in test performance across platforms — due to calibration issues and operator errors — remains a key restraint.
- Regulatory Complexity: Navigating divergent standards set by bodies such as the FDA (U.S.), EMA (Europe), and CFDA (China) poses significant challenges, particularly for smaller manufacturers seeking global expansion.
Segmentation Analysis
By Product
The blood glucose monitoring segment led the market with a 54.93% share in 2026, driven by rising diabetes prevalence and continuous innovation (e.g., Dexcom's ONE+ CGM launch in 2024). Infectious disease testing, hematology, and pregnancy & fertility testing segments are also expanding steadily.
By Sample
Blood-based testing dominated with a 77.05% share in 2026, given its diagnostic utility across HIV/AIDS, coronary artery disease, and organ function assessment. The urine segment is growing due to rising prevalence of chronic kidney disease — affecting approximately 35.5 million U.S. adults.
By End-User
Hospital bedside held the largest share at 40.50% in 2026, supported by rising adoption of advanced instruments in developed-country hospitals. The urgent care & retail clinics segment is expected to grow at the highest CAGR, with over 14,075 urgent care centers reported in the U.S. by end of 2022 — a 22.6% increase over 2019.
Regional Outlook
North America leads due to favorable reimbursement policies, advanced healthcare infrastructure, and a strong product approval pipeline. Asia Pacific is an emerging growth hub, driven by infectious and chronic disease burden; India's market alone is valued at USD 1.87 billion in 2026.
Competitive Landscape
The market is semi-consolidated, with key players including:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Abbott (U.S.)
- Danaher Corporation (U.S.)
- Becton Dickinson (BD) (U.S.)
- bioMérieux SA (France)
- Thermo Fisher Scientific Inc. (U.S.)
These companies are investing heavily in R&D, AI integration, and nanotechnology to strengthen their portfolios. Notable developments include Roche's CE-approved AI-enabled glucose monitoring system (July 2024) and NOWDiagnostics' FDA-approved home syphilis test (August 2024).
Key Market Opportunity
The integration of IoT into POC diagnostics stands out as a major opportunity, enabling real-time data transfer to EHR systems and supporting remote patient monitoring — particularly valuable for rural and underserved regions. The COVID-19 pandemic validated this approach by demonstrating the need for connected, decentralized diagnostic solutions.